L0_2016_Athens_Physics_Programme_V6

546-547 / 3107

Planning studies:
Improved dose distribution → clinical benefit?
 Organ avoided  less toxicity?
 Better target coverage  better tumor control?
 Lower toxicity  dose-escalation?
Clinical use of IMRT: What’s the scientific evidence?
Evidence
 …
Randomized controlled trials
IMRT vs. Non-IMRT?
12